Cynata completes patient enrollment for Phase 2 aGvHD clinical trial
Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease
Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease
The ChemiSphere app exemplifies how M-Trust technology transforms workflows into seamless digital experiences
The company operates a chain of mid-sized multi-speciality hospitals
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
The said certificate is valid for a period of 3 years and opens up the European and other markets for the company's products
The state-of-the-art facility is a 350-bedded, multi-specialty tertiary care hospital
This launch is part of the company's strategy to expand its nutraceutical portfolio
The reform is set to modernise how medicines are developed, authorised, and made available across the EU
Subscribe To Our Newsletter & Stay Updated